Pancreatic adenocarcinoma

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This phase II trial tests a treatment called HIPEC, where heated chemotherapy drugs are placed directly into the abdomen during surgery. It is for people with pancreatic cancer that has spread to the lining of the abdomen. The study will enroll 40 participants to see if this appr…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

This trial is testing a new type of radiation therapy that adapts daily to the exact shape and position of a pancreatic tumor. The goal is to deliver a high, tumor-killing dose while minimizing damage to nearby stomach and intestines. About 134 people with borderline resectable o…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

Researchers are comparing two chemotherapy approaches for people with advanced pancreatic cancer that has not worsened after three months of initial treatment with mFOLFIRINOX. One group continues mFOLFIRINOX, while the other switches to gemcitabine plus nab-paclitaxel. The trial…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …

This early-stage trial tests a new cell-based gene therapy called RR001 given after chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study aims to check safety and find the best dose in a small group of 9 participants. It is n…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This trial tests whether adding a procedure called irreversible electroporation (IRE) after chemotherapy helps people with locally advanced pancreatic cancer that cannot be surgically removed. About 60 adults who have stable or shrinking tumors after three cycles of chemotherapy …

This early-phase trial is testing whether injecting the MMR vaccine directly into pancreatic tumors is safe and can help shrink them. The study will include 20 adults with borderline resectable or unresectable pancreatic cancer who have already completed standard chemotherapy and…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a drug called M3814 combined with a special type of radiation for people with locally advanced pancreatic cancer (cancer that has spread nearby but not to distant organs). The goal is to find the safest dose and see if the combination helps stop tumor growth long…

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…

This phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …

This study tests a new device called DaRT that delivers a special type of radiation directly into pancreatic tumors. It is being combined with standard chemotherapy in 30 people with advanced or metastatic pancreatic cancer. The main goal is to see if the combination is safe, and…

This early-stage trial is testing whether a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy, is safe and feasible for treating pancreatic cancer after surgical removal. The vaccine is designed to train the immune system to recogniz…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This Phase 3 trial tests whether delivering chemotherapy directly into the artery feeding the tumor can help people with locally advanced pancreatic cancer live longer. Participants first get standard chemo and radiation, then are randomly assigned to either continue standard IV …

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests whether adding the drug BMS-986504 to standard chemotherapy can help control pancreatic cancer in people with a specific genetic change (MTAP deletion). About 60 adults with this type of pancreatic cancer will receive the combination before and after surgery or w…

This early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This early-stage trial tests a new treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The therapy uses a light-sensitive drug and a special light delivered through a thin tube into the blood vessels feeding the tumor. The goal is to see if it …

This study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…

This early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Particip…

This study tests an experimental drug called SG1906 in people with advanced solid tumors that have a specific protein (CLDN18.2) on their surface. The trial has two parts: first, finding the safest dose, and then checking for early signs that the drug can shrink tumors. About 60 …

This study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic canc…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This study tests a new way of giving chemotherapy to people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery. About 35 adults will receive two different chemo drug combinations in alternating cycles. The …

This study tests an experimental drug called GSK5764227, given alone or with other treatments, in 320 people with advanced gastrointestinal cancers that have not responded to prior therapy. The main goal is to see if the drug can shrink tumors and how safe it is. It is an early-s…

This early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This early-phase trial tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has worsened after standard treatment. The main goal is to check safety and find the right dose. About 64 adults will take part, and re…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-stage trial is testing a new chemotherapy drug called TR-002 in about 52 people with advanced solid tumors, including pancreatic cancer that has stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This Phase 3 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy can help people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). About 588 participants will be randomly assigned to receive either the drug combo o…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a device called the HistoSonics Edison System, which uses focused sound waves (histotripsy) to mechanically break apart pancreatic tumors without surgery. The trial will enroll 50 adults with advanced pancreatic cancer that cannot be removed surgically. The main …

This study tests a new drug called IBI343, given together with standard chemotherapy pills (capecitabine) and sometimes another chemo drug (oxaliplatin), in people whose advanced pancreatic cancer has stopped responding to initial treatment. The goal is to find a safe dose and se…

This early-phase trial tests a new device that is surgically placed on the pancreas to deliver the chemotherapy drug gemcitabine directly to the tumor. The goal is to see if this approach is safe and causes fewer side effects than standard IV chemo. The study involves 12 people w…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study tests a new approach for locally advanced pancreatic cancer: tiny radioactive sources placed directly into the tumor to deliver alpha radiation. The treatment is combined with standard chemotherapy. The main goal is to check safety in 40 participants, but researchers w…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study tests a combination of two drugs, pembrolizumab and olaparib, in people with advanced pancreatic cancer that has spread to other parts of the body. To join, participants must have tumors with high mutation levels or specific DNA repair problems. The goal is to see if t…

This study tests a new treatment called EGFR FPBMC for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer cells, then given back through an …

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. The goal is to see if it's safe and possible to place these tiny seeds in people with advanced pancreatic cancer that can't be removed by surgery. The study will enroll 15 par…

This study tests a new device that delivers a special type of radiation directly into pancreatic tumors. It is for people with advanced pancreatic cancer that cannot be removed by surgery. The main goals are to see if the procedure is safe and possible to do. About 15 participant…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This early study tests a new catheter system that delivers the chemotherapy drug Gemcitabine directly into or near pancreatic tumors. It includes 9 patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach is safe and feasible…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This study tests a new combination of drugs for people with advanced pancreatic cancer that has spread or come back. The treatment includes an experimental antibody (BMS-986340) plus immunotherapy and two chemotherapy drugs. The goal is to see if this mix is safe and shrinks tumo…

This early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the righ…

This phase 2 trial is testing a new drug combination for people with advanced pancreatic cancer that has a specific mutation called KRAS G12D. The treatment combines HRS-4642 (a drug that targets the mutated protein), nimotuzumab (an antibody that blocks a growth signal), and sta…

This early-phase trial tests a new way to deliver chemotherapy directly to the lining of the abdomen in people with pancreatic cancer that has spread there. The treatment, called PIPAC, uses a spray of chemotherapy drugs under pressure to reach tumor spots more effectively. The s…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests a new way to deliver radiation directly into pancreatic tumors using tiny radioactive beads. It is for people with locally advanced pancreatic cancer that has not spread but cannot be removed by surgery. The goal is to see if this approach is safe and feasible, a…

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This study is for people with metastatic pancreatic cancer that has spread. It tests a new combination of three drugs (S-1, nab-paclitaxel, and gemcitabine) to find the safest and most effective dose. About 70 participants will take part to see how well the treatment shrinks tumo…

This study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. About 56 adults with untreated pancreatic cancer will receive the combination. Th…

This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial ch…

This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injecti…

This study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and ci…

This early-phase trial tests adding the cholesterol-lowering drug pitavastatin to standard chemotherapy (gemcitabine and nab-paclitaxel) as maintenance therapy for people with advanced pancreatic cancer that cannot be removed by surgery. About 18 adults whose disease is stable af…

This study tests a new drug called ODM-212 combined with other cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. A…

This early-phase trial tests whether adding the targeted drug sotorasib (Lumykras) to standard chemotherapy is safe for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. About 15 participants will receive the combination as their first treatment. The …

This early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…

This study tests a new drug called ivonescimab, combined with targeted radiation and chemotherapy, for people with locally advanced pancreatic cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose of ivonescimab, then checking how well…

This study tests whether adding a low dose of erlotinib to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective for people with advanced pancreatic cancer. Participants are grouped by tumor type: those with 'basal-like' tumors get the new combo, while thos…

This study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline remova…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy before surgery can improve outcomes for people with resectable pancreatic cancer. About 40 participants will receive the drug combo, then undergo surgery to remove their tumor. The goal i…

This study tests whether giving two different chemotherapy combinations one after the other works better than the standard single combination for people with metastatic pancreatic cancer. About 162 adults aged 18 to 75 with confirmed disease will be randomly assigned to either th…

This phase 2 trial tests whether adding two drugs (defactinib and avutometinib) to targeted radiation therapy can help people with advanced pancreatic cancer live longer without their cancer growing. About 36 participants with borderline resectable or locally advanced pancreatic …

This phase 2 trial is testing whether high-dose radiation therapy, given after initial chemotherapy, can improve outcomes for people with locally advanced pancreatic cancer. About 43 participants whose tumors responded to chemotherapy will receive targeted radiation. Researchers …

This trial tests whether removing both the main pancreatic tumor and small spots in the liver or lungs after chemotherapy can help patients. It includes 40 people whose cancer has spread to only a few spots. Everyone gets the same treatment: chemo first, then surgery if the cance…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This phase 2 trial tests whether adding valproic acid and simvastatin to standard chemotherapy can help people with untreated metastatic pancreatic cancer live longer without their disease getting worse. About 240 participants will be randomly assigned to receive either the stand…

This study tests a new nanovaccine made from engineered bacteria that targets KRAS mutations in colorectal and pancreatic cancer patients who have had surgery and chemotherapy but are at high risk of their cancer coming back. The vaccine is designed to train the immune system to …

This early-phase trial tests whether adding leflunomide, a drug used for rheumatoid arthritis, to standard chemotherapy (gemcitabine) is safe for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 participants will receive the combination to find t…

This study tests a wearable device that creates electric fields (TTFields) combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that can be removed by surgery. Participants wear the device at least 18 hours daily and receive chem…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This study tests whether adding Acoustic Cluster Therapy (ACT) to standard chemotherapy can shrink inoperable pancreatic tumors. About 25 adults with locally advanced pancreatic cancer will receive both treatments. The goal is to see if the combination improves response rates and…

This study tests whether a major surgery that removes the pancreatic tumor and all visible cancer in the abdomen, followed by pumping heated chemotherapy drugs directly into the belly, is safe for people with pancreatic cancer that has spread to the lining of the abdomen. Twenty …

This study tests a short, high-dose radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The treatment uses protons or carbon ions to deliver a precise, powerful dose in only five sessions. Researchers hope this approach will imp…

This study tests whether a genetic test (PurIST) can help doctors choose the best chemotherapy for people with pancreatic cancer that can be surgically removed. About 84 participants will have their tumor genes analyzed from a biopsy sample, then receive a chemo plan matched to t…

This study tests whether a single, extremely high dose of radiation, guided by advanced MRI technology, can control liver tumors that have spread from other cancers better than the usual high dose. About 114 adults with up to 3 liver metastases will be randomly assigned to receiv…

This study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or met…

This early-phase trial is testing whether adding tumor treatment fields (TTF) — a device that delivers low-intensity electric fields to disrupt cancer cell division — to a three-drug chemotherapy regimen can safely control metastatic pancreatic cancer. About 40 adults with pancre…

This study is testing whether adding a precise, high-dose form of radiation (SBRT) after standard chemotherapy can help control locally advanced pancreatic cancer that cannot be removed by surgery. Eighteen adults with this type of cancer will receive chemotherapy first, and if t…

This study tests a drug called pemigatinib in people with advanced or metastatic pancreatic cancer that has certain changes in the FGFR gene. The drug aims to block these abnormal genes and stop tumor growth. About 40 adults will take the pill at home and be monitored through tel…

This study tests whether giving different chemotherapy drugs after pancreatic cancer surgery, based on how much tumor remains, can improve survival. About 390 patients who received chemo before surgery will be randomly assigned to one of two drug regimens. The goal is to reduce c…

This study tests a personalized cancer vaccine (XH001) given after surgery for pancreatic cancer, followed by immunotherapy drugs (ipilimumab, sintilimab) and chemotherapy (gemcitabine + capecitabine). The goal is to see if this combination can prevent the cancer from coming back…

This study is testing a new approach for people with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy (mFOLFIRINOX), an immunotherapy drug (pembrolizumab), and targeted radiation (SABR). After surgery, they continue …

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This study tests a new combination of drugs (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if the treatment can shrink the tumor enough for surgery and …

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

This Phase 3 trial tests whether Kinisoquin™, a supplement-like drug made from isoquercetin plus vitamins C and B3, can prevent dangerous blood clots in 480 people with advanced pancreatic cancer. Participants receive either Kinisoquin™ or a placebo alongside their first chemothe…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This early-phase trial is testing a new drug called OMTX705, which targets a protein on cancer cells, combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study will enroll 69 participants to first find the safes…

This phase 2 trial is testing a combination of five drugs (iparomlimab, tuvonralimab, chidamide, nab-paclitaxel, and gemcitabine) as a first treatment for people with metastatic pancreatic cancer. The study aims to see if this mix can shrink tumors and improve survival. It will e…

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…

This clinical trial is testing whether adding a device that delivers low-intensity electric fields (Tumor Treating Fields) to targeted radiation therapy can slow tumor growth in people with locally advanced pancreas cancer. Participants will receive radiation for five days and us…

This phase 2 trial tests an adaptive treatment plan for people with localized pancreatic cancer. Doctors adjust chemotherapy and radiation based on how the tumor responds, aiming to get more patients to successful surgery. The study enrolls 125 adults with resectable or borderlin…

This early-phase study tests a specially modified virus that is injected directly into pancreatic tumors during an endoscopic procedure. The goal is to find the safest dose that can control the disease without causing severe side effects. The trial involves 18 adults with pancrea…

This study tests a new approach for people with locally advanced pancreatic cancer whose first chemotherapy (AG) has stopped working. The treatment combines a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, with an investig…

This phase 2 trial tests a two-pronged approach for locally advanced pancreatic cancer that has stopped responding to standard chemotherapy. First, doctors freeze the tumor using cryoablation, then give patients an experimental antibody called Apalulizumab that targets two immune…

This trial tests whether giving three treatments together—two medicines and a surgical patch—can lower the risk of major complications after Whipple surgery for pancreatic cancer and other tumors. The study includes 400 high-risk patients with a small pancreatic duct. If successf…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer. The device is worn at home for at least 18 hours a day and aims to disrupt cancer cell division. The trial will check if the combina…

This phase 2 trial tests a two-step approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. First, patients receive two powerful chemotherapy regimens in sequence (GEMBRAX then FOLFIRINOX). Then, those whose cancer does not worsen get MRI-gu…

This study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…

This study tests two different cancer vaccines (GVAX and a KRAS peptide vaccine) given with two immunotherapy drugs (balstilimab and AGEN2373) in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if the combination helps the…

This phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arth…

This early-stage trial tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy tumor cells, combined with standard chemotherapy drugs (gemcitabine or FOLFIRINOX). The study includes 20 adults with stage III pancreatic cancer that hasn't …

This study tests a new way to treat advanced pancreatic cancer by combining two approaches: a drug called nivolumab that helps the immune system fight cancer, and a procedure called irreversible electroporation that uses electric pulses to destroy tumor cells. The goal is to see …

This early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…

This study tests whether giving chemotherapy and radiation before surgery can help surgeons remove all of the pancreatic cancer. About 30 adults with resectable pancreatic cancer will receive the drugs gemcitabine and nab-paclitaxel plus targeted radiation, then surgery, then mor…

This early-phase study tests a three-part drug combination for people with advanced pancreatic cancer who haven't had chemotherapy yet. The drugs include elraglusib (a targeted agent), retifanlimab (an immunotherapy), and a standard chemo regimen called mFOLFIRINOX. The main goal…

This study tests a two-step surgery for people with pancreatic or related cancers. Instead of the standard partial removal, doctors remove the entire pancreas and then transplant the patient's own insulin-making cells into the liver. The goal is to prevent a common complication (…

This phase II study tests a new drug called IBI343, which targets a protein on cancer cells, combined with standard chemotherapy (gemcitabine and albumin-bound paclitaxel) in 64 people with advanced pancreatic cancer. The trial has two parts: a safety lead-in and a randomized ext…

This phase II study tests whether a combination of two drugs, niraparib and ipilimumab, can slow tumor growth in people with metastatic pancreatic cancer whose disease has not worsened after platinum-based chemotherapy. About 68 participants will be randomly assigned to receive e…

This phase 2 trial tests whether a higher dose of proton radiation combined with the oral chemotherapy drug capecitabine can help people with unresectable pancreatic cancer live longer and possibly become candidates for surgery. The study enrolls 60 patients whose tumors cannot b…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

Researchers are testing whether a 3D imaging model called 3D-PANC MSP is better than standard CT scans at showing how pancreatic tumors respond to chemotherapy before surgery. The study includes 70 patients with borderline or locally advanced pancreatic adenocarcinoma who have re…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study tests two new ultrasound techniques to help doctors tell the difference between common pancreatic cancer and other types of pancreatic growths. About 150 adults with a solid pancreatic mass will get these advanced scans. The goal is to see if these methods can improve …

This study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI-46 to highlight pancreatic cancer cells. The goal is to see if this scan can find tumors more accurately than current methods. About 130 adults with early-stage pancreatic cancer will get the scan…

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it wor…

This study is testing a new blood test that looks at tiny particles called exosomes and their microRNA content, analyzed by machine learning, to detect pancreatic cancer early. It involves 600 people at high risk due to family history or pancreatic cysts. The goal is to see if th…

This study tests whether a high-powered imaging technique called ultra-high resolution optical coherence tomography (OCT) can detect tiny, early-stage pancreatic cancers in tissue samples removed during surgery. Researchers will compare OCT images with standard lab analysis and a…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study tests whether a new type of PET scan using a tracer called 68Ga-FAPI-46 can more accurately detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. The goal is to see if this scan changes how doctors classify the cancer stage and pl…

This study tests a dye called panitumumab-IRDye800 that attaches to pancreatic cancer cells and makes them glow under a special camera during surgery. The goal is to help surgeons see and remove all cancer tissue, including tiny spots that might otherwise be missed. About 27 adul…

This study tests a new type of PET scan that uses a special tracer to light up a protein called FAP, found on pancreatic tumor tissue. The goal is to see if this scan can detect cancer spread that standard CT scans miss. Researchers will compare the new scan with CT in 60 adults …

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study tests a new imaging agent called FL-091, which targets a protein (NTSR1) found on some cancer cells. Researchers will use it with PET or SPECT scans to see if it can better detect and stage cancers like head and neck, colorectal, and pancreatic cancer. About 100 adults…

This study tests if giving the drug lanreotide before pancreatic surgery can prevent a common complication called a pancreatic fistula, which is a leak of digestive fluids. About 274 people with pancreatic cancer or precancerous lesions will be randomly assigned to receive either…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether telehealth self-management coaching sessions can improve quality of life for people with metastatic pancreatic cancer and their family caregivers. Participants will attend virtual coaching sessions focused on managing physical symptoms, emotional well-bei…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests whether a personalized exercise program given before, during, and after Whipple surgery (a major operation for pancreatic cancer) helps patients recover faster and start chemotherapy sooner. Adults scheduled for Whipple surgery will receive an exercise plan tailo…

This study tests whether a community health worker can help people newly diagnosed with pancreatic cancer feel better and manage their symptoms. The health worker meets with patients and their caregivers to address physical, emotional, and practical concerns, and helps coordinate…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

Researchers are creating a biobank of biological samples and clinical data from 2000 adults with various pancreatic conditions, including pancreatitis and pancreatic cancer. The goal is to investigate how genetic predisposition and environmental exposures interact to trigger thes…

This study compares two ways of monitoring pancreatic cysts—more frequent versus less frequent scans—and looks for biomarkers in the blood that might help predict cancer risk. About 770 adults aged 50 to 75 with at least one cyst will take part. The goal is to find out which moni…

This study aims to find pancreatic cancer earlier in people who are at higher-than-average risk due to family history or genetic mutations. Researchers will collect blood samples and health data from 30,000 participants over time to build a biobank. The goal is to improve early d…

This registry is collecting information from 1,500 people with advanced pancreatic cancer in Austria to see how different chemotherapy treatments work in everyday practice. Researchers will track which treatments are used, how well they work, and what side effects occur. The goal…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study tests whether a dye called indocyanine green can help predict pancreatic leaks after pancreas surgery. Participants will receive the dye during surgery, and doctors will measure how well the pancreas tissue is getting blood flow. The goal is to see if this dye can iden…

This study is looking at why some people with advanced cancer lose weight and muscle, a condition called cachexia. Researchers will follow 800 patients with advanced lung, pancreatic, or colorectal cancer to see if there are distinct subtypes of cachexia based on symptoms, biomar…

This study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…

This study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…

This study is looking for genetic differences that may explain why many people with pancreatic cancer develop severe muscle wasting (cachexia). Researchers will collect blood samples from 100 patients to analyze their DNA. The goal is to find markers that could lead to earlier de…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study is testing whether wearing a fitness tracker (like a Fitbit) can give doctors a better picture of how active cancer patients are, and whether that activity level relates to how well they are doing overall. About 590 people with various cancers will wear activity monito…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study is analyzing tissue and blood samples from 64 people with pancreatic cancer that has spread. Researchers want to understand how cancer cells change their energy use and interact with surrounding cells. The goal is to find new targets for treatment and better ways to pr…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well pancreatic cancer patients respond to chemotherapy. Researchers will track ctDNA levels before, during, and after treatment in 500 patients whose cancer has not spread. The goal …

This trial investigates whether a lidocaine infusion given during pancreatic cancer surgery can affect circulating tumor cells (CTCs) — cancer cells that may travel through the blood. Researchers will compare lidocaine to a saline placebo in patients undergoing robotic pancreatec…

This study tests whether a mobile app called MyCap can help track the time patients spend on pancreatic cancer treatment, including appointments, travel, and waiting. Thirty adults with pancreatic cancer who are on active treatment will use the app daily for 8 weeks. The goal is …

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study is creating a large database of 1,000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long patients live and how long their cancer stays under control. The goal is to learn which treatments work best for differen…

This study looks at tumor samples from 300 people with exocrine pancreatic cancer to find links between genetic changes in the tumor and how the disease behaves. Researchers will use advanced DNA sequencing to analyze samples already collected from surgeries and biopsies. The goa…

This observational study is analyzing tumor and blood samples from 50 people with pancreatic cancer to measure levels of certain proteins called convertases. Researchers want to see if these protein levels are linked to immune cells in the tumor, which could help predict how the …

This study collects blood samples from 30 adults with pancreatic cancer to build a library for future research. The goal is to store specimens and health data together, creating a powerful tool for scientists to study the disease. Participants must be patients at the University o…

The PREDICT study is creating a registry and biospecimen bank for people with pancreatic disease or at high risk for pancreatic cancer. Researchers will collect blood, tissue, urine, and other samples from 1,000 participants to study the causes and biology of the disease. This is…

This study collects tumor tissue and medical information from 1,500 people with pancreatic cancer. The goal is to build a large biobank that scientists can use to better understand the disease and develop new treatments. Participants undergo standard diagnostic procedures, and no…

This study collects blood, tissue, and health information from 20,000 people with pancreas diseases like pancreatic cancer, pancreatitis, or cysts. The goal is to create a large database and sample bank that researchers can use to better understand these conditions and develop be…

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…

This study explores whether using MRI scans before each radiation treatment is practical and helpful for people with liver or pancreatic cancer. About 30 participants will receive up to 5 extra MRIs alongside their standard radiation therapy. Researchers will measure patient sati…

This study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…

This study is observing 800 people with advanced lung, colorectal, or pancreatic cancer to understand why some lose weight and muscle (cachexia). Researchers hope to find distinct subtypes of cachexia, which could lead to better, more personalized treatments in the future. Partic…

This study looks at patients with locally advanced pancreatic cancer that cannot be removed by surgery at first. After at least 4 months of chemotherapy, if the tumor shrinks enough, doctors may consider surgery. The goal is to see if this approach helps patients live longer and …

This study aims to collect medical history, family history, and blood or urine samples from 10,000 people with or at risk for pancreatic cancer. Researchers will use this information to look for genetic and environmental factors linked to the disease. Participants may also be ask…